Sacituzumab govitecan in metastatic triple negative breast cancer (TNBC): Four design features in the ASCENT trial potentially favored the experimental arm

The ASCENT trial reports impressive results with a median overall survival (OS) increased from 6.7 months to 12.1 months with sacituzumab govitecan over single-agent chemotherapy, in metastatic triple negative breast cancer (TNBC) patients in second and subsequent line of therapy. We described desig...

Descripción completa

Detalles Bibliográficos
Autores principales: Olivier, Timothee, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2021
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531666/
https://www.ncbi.nlm.nih.gov/pubmed/34688044
http://dx.doi.org/10.1016/j.tranon.2021.101248

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8531666/
https://www.ncbi.nlm.nih.gov/pubmed/34688044
http://dx.doi.org/10.1016/j.tranon.2021.101248

Ejemplares similares